Document is current
Any future updates will be listed below
-
Authors
Xie, Jinpeng
Wang, Lihong
Zhao, Shuaifei
Wang, Jue
Cheng, Yang
Xu, Lei
Kou, Ting
Chen, Ying
Ying, Yuxiu
Xin, Xiaoshuang
Zhang, Ting
Xu, Xu
Lu, Dandan
Hu, Xiangyu
Zhang, Yusu
Qiu, Chenyu
Wang, Jun
Cheng, Gu
Zhou, Jing
Lei, Siyun
Lyu, Qiqi
Li, Jingtao
Pan, Yihuai
Cao, Tong
-
Funding
Funding for this research was provided by:
Zhejiang Province (2024SSYS0056)
Zhejiang Provincial Oujiang Lab (OJQD2022003)
- License Information
-
More Information
Article History
Received: 17 August 2025
Accepted: 17 December 2025
First Online: 8 January 2026
Declarations
:
: The human embryonic stem cell line H1 (NIH registration number: NIHhESC-10-0043) used in this study was obtained from the WiCell Research Institute (Madison, WI, USA). According to the public information available on the official WiCell website, the derivation and distribution of this cell line were conducted in full compliance with ethical guidelines. Specifically, the collection and use of the embryos were approved by the Institutional Review Board (IRB) of the originating institution, in accordance with the NIH guidelines and the International Society for Stem Cell Research (ISSCR) standards. The H1 cell line is listed in the NIH Human Embryonic Stem Cell Registry, and was derived from surplus embryos donated voluntarily by individuals who provided written informed consent for research purposes, with no financial compensation. Therefore, no additional institutional ethical approval was required for the use of this commercially available cell line.
: All the authors approved the publication.
: The authors declare no competing interests.
